Race Oncology (RAC) - Managing Director and CEO, Phil Lynch (left)
Managing Director and CEO, Phil Lynch (left)
Source: Race Oncology
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • A second independent study has confirmed the inhibiting capabilities of Race Oncology’s (RAC) drug, Bisantrene
  • A research team at the University of Chicago demonstrated Bisantrene’s ability to inhibit the Fat Mass and Obesity associated protein (FTO)
  • This supports the City of Hope Hospital’s 2020 hypothesis that Bisantrene can inhibit the FTO involved in skin cancer development
  • This additional independent confirmation will help to progress Race Oncology’s clinical plans for Bisantrene 
  • Race Oncology is up 10.78 per cent and trading at $3.39 per share

A second independent study has confirmed the inhibiting capabilities of Race Oncology’s (RAC) drug, Bisantrene.

In 2020, Professor Chen and his team at the City of Hope Hospital identified Bisantrene as a potent inhibitor of the Fat Mass and Obesity-associated protein (FTO). The FTO is hypothesised to have a major role in the development of skin cancers, but the results from the City of Hope Hospital needed to be replicated in order for this potential discovery to be taken seriously.

There is currently a replication crisis in cancer research, meaning that many exciting potential discoveries have not been successfully repeated in independent laboratories. However, according to details in a recent scientific publication in the journal Nature Communication, an independent study has been able to support the theory about Bisantrene as an FTO inhibitor.

A research team at the University of Chicago, led by Professors Chuan He and Yu-Ying He, recently identified that the FTO plays a critical role in developing skin cancers caused by low-level arsenic exposure. The team was also able to demonstrate that Bisantrene-targeted inhibition of FTO limited the growth of these skin cancers, in both cell cultures and mice.

Race Oncology’s Chief Scientific Officer, Dr Daniel Tillett, commented that independent confirmation of Bisantrene’s ability to target FTO and treat skin cancer is of great importance.

“Many scientists and pharmaceutical companies are sceptical of potential cancer breakthroughs until they have been replicated by an independent group of researchers,” he said.

“This new paper repeating the earlier FTO work of the City of Hope Hospital is a major step forward for our clinical plans for Bisantrene,” he added.

Race Oncology is up 10.78 per cent, trading at $3.39 per share at 11:21 am AEST.

RAC by the numbers
More From The Market Herald
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.

" Beamtree (ASX:BMT) signs A$10.1m RippleDown contract with Ampath

Beamtree (ASX:BMT) has signed a US$7 million (A$10.1 million) five-year contract with Ampath for its RippleDown…